Crossmark

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Crossref DOI link: https://doi.org/10.1007/s40262-019-00755-3

Published Online: 2019-04-06

Published Print: 2019-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taneja, Amit

Desrivot, Julie

Diderichsen, Paul Matthias

Blanqué, Roland

Allamasey, Lisa

Fagard, Liesbeth

Fieuw, Ann

Van der Aar, Ellen

Namour, Florence
License Information

Text and Data Mining valid from 2019-04-06
More Information

Article History

First Online: 6 April 2019

Compliance with Ethical Standards

:

: No external funding was received for the preparation of this article or conduct of this study.

: Amit Taneja, Sonia Dupont, Roland Blanqué, and Florence Namour are employees of Galapagos SASU. Julie Desrivot is an employee of Pierre Fabre. Liesbeth Fagard, Ann Fieuw, and Ellen Van der Aar are employees of Galapagos NV. Lisa Allamasey is an employee of ALTEN Belgium. Paul Matthias Diderichsen is an employee of Certara Strategic Consulting.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the clinical studies referred to in this article.

Document is current

Any future updates will be listed below